Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vencanna VenturesVENCF +80.00% Equity-to-Asset is 0.88 as of Jan. 2026, which is 7% above its 10-year median of 0.82. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Vencanna Ventures ranks better than 91.76% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vencanna Ventures's Total Stockholders Equity for the quarter that ended in Jan. 2026 was $2.45 Mil. Vencanna Ventures's Total Assets for the quarter that ended in Jan. 2026 was $2.79 Mil.
Therefore, Vencanna Ventures's Equity to Asset Ratio for the quarter that ended in Jan. 2026 was 0.88.
The historical rank and industry rank for Vencanna Ventures's Equity-to-Asset or its related term are showing as below:
VENCF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.62 Med: 0.82 Max: 1
Current: 0.88
During the past 13 years, the highest Equity to Asset Ratio of Vencanna Ventures was 1.00. The lowest was 0.62. And the median was 0.82.
VENCF's Equity-to-Asset is ranked better than 91.76% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs VENCF: 0.88
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vencanna Ventures Equity-to-Asset Related Terms
Vencanna Ventures Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Vencanna Ventures's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vencanna Ventures's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vencanna Ventures Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vencanna Ventures's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vencanna Ventures's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vencanna Ventures's Equity to Asset Ratio for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vencanna Ventures (VENCF) has a Equity-to-Asset of 0.88 as of Jan. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vencanna Ventures and its competitors. This is near median its historical median of 0.82. Over the past decade, Vencanna Ventures' Equity-to-Asset has ranged from 0.62 to 1.00. According to the industry distribution chart, Vencanna Ventures ranks #83 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Vencanna Ventures' Equity-to-Asset too high?
Vencanna Ventures' current Equity-to-Asset of 0.88 is near median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 1.00. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Vencanna Ventures' value of 0.88 is 44.3% above this industry median. Based on the distribution chart, Vencanna Ventures ranks #83 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Vencanna Ventures' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vencanna Ventures ranks #83 out of 1007 companies for Equity-to-Asset. This places Vencanna Ventures in the top 8% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Vencanna Ventures' value of 0.88 is 44.3% above this benchmark. Historically, Vencanna Ventures' own Equity-to-Asset has ranged from 0.62 to 1.00 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.61, Vencanna Ventures has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vencanna Ventures's current Equity-to-Asset of 0.88 is 44.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vencanna Ventures and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vencanna Ventures's current Equity-to-Asset is 0.88, which is near median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vencanna Ventures stock overvalued right now?
Vencanna Ventures (VENCF) has a current Equity-to-Asset of 0.88. The current Equity-to-Asset is 0.88, which is near median its 10-year median of 0.82 and 44.3% above the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Vencanna Ventures (VENCF), the current Equity-to-Asset is 0.88 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vencanna Ventures Inc aims to provide investors with a diversified, high-growth, cannabis investment plan through strategic investments and acquisitions focused throughout the value chain (cultivation, processing, and distribution), including ancillary businesses. The company generates the majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VENCF has been successfully added to your 
